New research from the University of Oklahoma identifies a protein in liver cells that appears to help drive the development of liver cancer associated with obesity-related fatty liver disease. The finding, published in Hepatology, points to the protein as a potential new therapeutic target for liver cancer.

Scientists, clinicians, and patient advocates from across the pediatric sarcoma community called for bridging cancer drug discovery and treatment through a unified clinical infrastructure. After meeting at Cold Spring Harbor Laboratory’s Banbury Center, the group outlined future research priorities and healthcare opportunities in an article for the journal Genes & Development.

In vivo immune cell engineering directly reprograms endogenous immune cells, bypassing individualized ex vivo manufacturing and opening a path toward more accessible and scalable cell therapies. This review summarizes cell-specific engineering strategies, compares viral and non-viral delivery platforms, highlights emerging applications in cancer, autoimmune and degenerative diseases, and discusses the key challenges that must be overcome for clinical translation.